It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: angelchemuel
a reply to: Soloprotocol
And none of them related to travel apparently. They are calling it a community infection!
Rainbows
Jane
originally posted by: angelchemuel
a reply to: Soloprotocol
And none of them related to travel apparently. They are calling it a community infection!
Rainbows
Jane
Can be cited as: Goldstein L., Re-analysis of Molnupiravir Trials, Phase II/III; defyccc.com, PREPRINT, [link], 2021
Abstract
This is a re-analysis of the data from Molnupiravir trials, presented by the FDA.
The trials’ sponsor modified the pre-registered protocol, so the results will appear more beneficial than they are. To this end, results from patients recruited by August 5 were reported as a separate trial – here referred to as Trial 1. Thus, the data from patients recruited after August 5 should also be presented as a separate trial – here referred to as Trial 2.
In this second trial, the Molnupiravir arm had 32.5% higher relative risk of hospitalization or death compared to the placebo arm.